HighTide Therapeutics, Inc (HTTIF) Fair Value & Analysis

Healthcare · US · Market cap $178M

A solid business, screening 152% undervalued on our models.

What matters now

• The price is below even our cautious bear case ($0.6400). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.
• A fairly wide model range ($0.6400 to $1.22) leaves room in how you read the outcome.

Price vs Fair Value (4 months)

White line = price, green steps = our fair value per fiscal year. As of Jul 17, 2026.

How to read this chart

4‑month range $0.3499 – $0.4206 · fair‑value band $0.6400 – $1.22 · the $0.3893 price screens below the $0.9800 fair value. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

HighTide Therapeutics, Inc (HTTIF) currently trades at $0.3893, while our model-based Fair Value estimate is $0.9800, implying the stock looks roughly 151.7% undervalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

It earns a return on equity of -58.9%. Fundamentals as of Jul 17, 2026

Our scenario range runs from $0.6400 (bear case) to $1.22 (bull case); at $0.3893, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 152%, HTTIF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China.

Full company description

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disease. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTD1804 that is in preclinical trial to treat obesity; and HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

HighTide Therapeutics, Inc reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$232M in FY2025.

Watch HTTIF: get an alert when its fair value changes →

Peer Group

Biotechnology · 601 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.